- ￥22
- ProSci
- 美国
- PSI-10-182-0.1mg
- 2025年07月05日
企业认证
相关产品推荐更多 >
iFluor™ 820 Anti-human CD47 Antibody *HI172*/iFluor™ 820 Anti-human CD47 Antibody *HI172*/iFluor™ 820 Anti-human CD47 Antibody *HI172*
询价
Itpr1单克隆抗体, 克隆号S24-18 (PE/ATTO 594) | Itpr1 monoclonal antibody, clone S24-18 (PE/ATTO 594)
询价
iFluor™ 532 Anti-human CD116 Antibody *4H1*/iFluor™ 532 Anti-human CD116 Antibody *4H1*/iFluor™ 532 Anti-human CD116 Antibody *4H1*
询价
Interleukin 22 Receptor (IL22R) Antibody/Interleukin 22 Receptor (IL22R) Antibody/Interleukin 22 Receptor (IL22R) Antibody
询价
LGR6 抗体-LGR6 Antibody
￥22
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Chimeric / MS4A1 [Homo sapiens]
- 保存条件：
Store at -80℃
- 保质期：
1年
- 级别：
科研级别
- 库存：
100
- 供应商：
艾美捷科技
- 抗体英文名：
Rituximab (MS4A1) Antibody, Monoclonal
- 抗体名：
Rituximab (MS4A1) Antibody, Monoclonal
- 规格：
0.1mg
Rituximab (MS4A1) 抗体, 单克隆，Rituximab (MS4A1) Antibody, Monoclonal，Rituximab (MS4A1) 抗体, 单克隆,Rituximab (MS4A1) Antibody, Monoclonal
产品名称：Rituximab (MS4A1) 抗体, 单克隆-Rituximab (MS4A1) Antibody, Monoclonal
产品货号：PSI-10-182-0.1mg
产品规格：0.1mg
背景资料：Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences 6, Label. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) 8, however, has now been approved for a variety of conditions Label. On November 28, 2018, the US FDA approved Truxima, the first biosimilar to Rituxan (Rituximab) 7.Rituximab is a monoclonal antibody that targets the CD20 antigen, which is expressed on the surface of pre-B and mature B-lymphocytes 1, 2, 3, Label. After binding to CD20, rituximab mediates B-cell lysis (or breakdown). The possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC) Label.
保存建议：Rituximab (MS4A1) 抗体, 单克隆-Rituximab (MS4A1) Antibody, MonoclonalStore at -80℃
应用类型：
点击：Rituximab (MS4A1) 抗体, 单克隆-Rituximab (MS4A1) Antibody, Monoclonal查看更详细产品说明，更多应用、储存、价格、货期等信息请垂询艾美捷科技有限公司。更多ProSci公司特色试剂盒、特色抗体以及特色试剂等产品评论，请点击查看艾美捷特色产品中心。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验指仅对一种抗原决定基的纯粹的抗体。这类抗体不可能通过将抗原 胞的 Hybridoma，在试管内制成了纯粹的单克隆抗体。用某种抗原使动物产生免疫感应，对应于抗原之不同部分可制成各种不同的抗体复合体。然而，因为一个产生抗体的细胞，只能产生一种抗体，所以骨髓肿瘤细胞与产生抗体细胞间的细胞杂种，可形成边产生抗体边增殖的 hybridoma，将每个杂种细胞进行克隆（无性繁殖系）培养，则一个克隆的细胞群只由单种类产生同一抗体的细胞所组成，这样得到的就是单克隆抗体。此抗体在测定
monoclonal antibodies have improved responses with minimal toxicities. For instance, Rituximab (chimeric anti-CD20 monoclonal antibody) was the first FDA-approved monoclonal antibody for the treatment of patients with non-Hodgkin’s lymphoma (NHL
相对应的抗体，所以一个B细胞与骨髓瘤细胞融合而成的单个杂交瘤细胞，也只产生某种单一的抗体。采用适当方法把杂交瘤细胞分离出来，进行单个细胞培养，使之大量繁殖，则在该培养液中增殖而形成的细胞克隆，只产生完全均一的、单一特异性的抗体，即单克隆抗体。若把能产生特异性抗体的单克隆杂交瘤进行大量培养，或注入原系动物腹腔中，则杂交瘤仍以腹水型方式生长，在培养液或腹水中会含有大量单克隆抗体。用杂交瘤技术制备出来的单克隆抗体纯度高、专一性强、效价高，使用时可免除不同细胞及微生物种或株间血清学上的交叉反应，大大提高了诊断
技术资料暂无技术资料 索取技术资料
